CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL).
Jia Ruan(Cornell University), John P. Leonard(New York University), Ethel Cesarman(Cornell University), Amy Chadburn(Cornell University), Rubén Niesvizky(Cornell University), Rebecca Elstrom(Acentech (United States)), Julie M. Vose(University of Nebraska Medical Center), Morton Coleman(Cornell University), Scott Ely(NewYork–Presbyterian Hospital), Ann S. LaCasce(Otsuka (Japan)), Jennifer O’Loughlin(Centre Hospitalier de l’Université de Montréal), Richard R. Furman(Cornell University), Ying‐Kuen Cheung(Columbia University), Peter Martin(Northwestern University)
Cited by 6
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k